The trial will assess the drug’s ability to prevent infection among those who have had close contact to an infected person, such as a patient’s housemate

The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of Covid-19, in a news release on Monday. Specifically … Read More

Loading

Follow by Email
Pinterest
LinkedIn
Share